#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Normand Davidzon Email
VP, Engineering Technology . Mesoblast
Melbourne,
Locationn***************@mesoblast.com
Primary EmailHow to contact Normand Davidzon
Join and see Normand's contact info for free!Current Roles
Employees:
84Revenue:
$9.7MAbout
Mesoblast; (ASX: MSB; Nasdaq:MESO) is a world leader in innovative cell-based medicines. We have leveraged our proprietary technology platforms based on specialized cells known as mesenchymal lineage adult stem cells (MLCs) to establish what we believe is the most advanced cellular medicines portfolio in the industry. Our ‘off-the-shelf' products are allogeneic - meaning cells from one donor may be used in many different recipients without the need for matching. Our licensee in Japan has launched its MLC-based product for acute graft versus host disease in children and adults in Japan. It is the first allogeneic cell-based product in Japan to be fully approved in Japan. We believe we are well positioned to have the first industrially manufactured allogeneic cell-based product approved in the United States. Our lead product candidates under investigation are: - MPC-150-IM for chronic heart failure - MPC-06-ID for chronic low back pain due to disc degeneration - MSC-100-IV for acute graft versus host disease - MPC-300-IV for biologic refractory rheumatoid arthritis, and diabetic nephropathy We also have a strong emerging pipeline of products for follow-on indications. Led by Chief Executive Silviu Itescu, a pioneer in cellular medicines, the Mesoblast management team has substantial experience in all aspects of biopharmaceutical development. Cell-based therapies, cellular medicines, Mesenchymal Lineage Adult Stem Cells, regenerative medicineMesoblast Address
505 Fifth AvenueMelbourne, null
AU